Definitive Healthcare (NASDAQ:DH) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Definitive Healthcare (NASDAQ:DH) from a buy rating to a hold rating in a report released on Saturday morning.

A number of other equities research analysts have also recently commented on the company. Bank of America reiterated an “underperform” rating and issued a $0.70 price target on shares of Definitive Healthcare in a research note on Monday, June 29th. Weiss Ratings restated a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Wednesday, June 3rd. Robert W. Baird set a $1.10 price objective on shares of Definitive Healthcare in a report on Friday, May 8th. Zacks Research upgraded shares of Definitive Healthcare from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. Finally, Barclays decreased their price objective on shares of Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a research report on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have given a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $2.47.

Definitive Healthcare Trading Down 5.1%

NASDAQ:DH opened at $0.72 on Friday. Definitive Healthcare has a 52 week low of $0.62 and a 52 week high of $4.70. The firm has a 50 day moving average of $0.83 and a 200 day moving average of $1.30. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.81. The stock has a market capitalization of $76.02 million, a price-to-earnings ratio of -0.44, a PEG ratio of 10.11 and a beta of 1.33.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.03. The business had revenue of $55.93 million for the quarter, compared to analyst estimates of $55.02 million. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. As a group, sell-side analysts anticipate that Definitive Healthcare will post 0.05 earnings per share for the current fiscal year.

Institutional Trading of Definitive Healthcare

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DH. BNP Paribas Financial Markets grew its position in shares of Definitive Healthcare by 32.9% in the third quarter. BNP Paribas Financial Markets now owns 17,811 shares of the company’s stock valued at $72,000 after purchasing an additional 4,407 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in Definitive Healthcare by 109.3% during the fourth quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock worth $32,000 after buying an additional 5,970 shares during the last quarter. Invesco Ltd. grew its holdings in Definitive Healthcare by 5.8% in the 4th quarter. Invesco Ltd. now owns 117,427 shares of the company’s stock valued at $337,000 after buying an additional 6,400 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Definitive Healthcare in the 2nd quarter worth $32,000. Finally, Creative Planning increased its stake in shares of Definitive Healthcare by 41.7% in the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock worth $112,000 after acquiring an additional 8,428 shares during the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.